precursor contains an N-terminal 24-amino acid signal protein, a 29-amino acid PACAP-related peptide and PACAP in the C-terminal domain. The precursor protein can be metabolized by prohormone convertase enzymes to biologically active PACAP-27 or PACAP-38 (prepro-PACAP ), which contains PACAP-27 and an additional 11 amino acids at the C-terminal [2 ] . Human PACAP is derived from a 176-amino acid precursor protein (preproPACAP) and the gene is located on chromosome 18p11 which consists of five exons, four introns, with PACAP38 encoded for by exon 5 [2 ,8 ] . The human VIP gene is located on chromosome 1p11 and consists of seven introns and six exons, five of which are coding [8 ] . Both PACAP and VIP peptides, like other members of this superfamily, show secondary structure, showing long a-helical structure at the COOH terminus [9, 20, 21] . VIP is proposed to have two b-turns at residues 2-5 and 7-10, followed by a long a-helical at residues, whereas 11-26 PACAP-27 has a b-turn in amino acids 9-12, and a-helical regions in amino acids 12-14, 15-20 and 22-24 [2 ,9,22] . A number of structure-function studies have examined and explored the key amino acids responsible for high-affinity receptor interaction and activation for both peptides [9, 11, [20] [21] [22] [23] which have lead to simplified analogs which are more metabolically stable [9, 10, 24, 25] . The 61-amino acid maxadilan, isolated from salivary glands of the sand fly, is a selective PACAP receptor agonist but has little sequence homology to PACAP [26] .
VIP/PACAP receptors
Vasoactive intestinal peptide and PACAP's actions are mediated by three classes of G-protein-coupled receptors: PAC1-R, VPAC1-R, and VPAC2-R, with PACAP interacting with high affinity with all three, but VIP has high affinity for only VPAC1-R/VPAC2-R [2 ,5 ,27] . Activation of each class is coupled to adenylate cyclase activation; however, VPAC1-R and VPAC2-R activation in some cells is also coupled to activation of phospholipase C or D, and activation of PAC1-R is characteristically coupled to activation of phospholipase C [2 ,5 ] . The PAC1-R has splice variants in intracellular loop 3 (IC3). The regular (Reg) receptor has 467 amino acids [2 ] . SV-1 or the hip receptor has a 28-amino acid insert in IC3; SV-2 or the hop receptor (HOP1) has a different 28-amino acid insert in IC3 and SV-3 or the hip-hop receptor has both 28-amino acid inserts in IC3. PACAP addition to cells transfected with PAC1-R SV-2 strongly increased phosphoinositol turnover, whereas cells transfected with Reg, SV-1 or SV-3 had a weaker Ca 2þ response [28] . Also, extracellular loop 1 (EC1) deletions or splice variant insertions exist [29] . Ushiyama et al. [30, 31] expressed variants of the EC1 domain (N or S form) and variants of IC3 (Reg or HOP1). The resulting four PAC1-R isoforms (N/Reg, N/HOP1, S/Reg or S/HOP1) bound PACAP-27 with high affinity. N/Reg, S/Reg, or S/HOP1 but not N/HOP1 strongly increased cyclic adenosine monophosphate (cAMP). These results indicate that alterations in EC1 or IC3 do not affect PAC1-R binding, but do affect second messenger production. Activation of VPAC1-R/VPAC2-R and PAC1-R can also activate mitogen-activated protein kinase (MAP) kinases, tyrosine kinases, transactivate growth factor receptors as well as activate calcium channels, RHOA GTPASes and Src [2 ,5 ]. All three receptor classes are widely expressed in both peripheral tissues and in the CNS, with the VPAC1-R predominately expressed in smooth muscle layers of organs and blood vessels [5 ] .
Functions/roles of VIP/PACAP and their receptors revealed by knockout studies
Results from VIP, PACAP or their receptor knockout studies from each of the different areas of physiological/ pathophysiological effects of VIP/PACAP are briefly summarized.
Knockout studies: general
Vasoactive intestinal peptide and PACAP are described to have a wide range of effects in both the CNS and peripheral tissues, in both normal tissues and under pathologic conditions [2 ,6,12,32-34] . Which of these are physiological, pathophysiological or pharmacological had been difficult to determine because of the lack of high-affinity potent antagonists. Recently, specific VPAC1-R, VPAC2-R or PAC1-R receptor knockout animals have been extensively studied and provide a number of important insights into their functions. Some of these results will be briefly reviewed here.
Knockout studies: metabolic/endocrine effects VIP/PACAP Both VIP and PACAP are found in the islets of Langerhans and in accompanying nerves, as well as VPAC1-R, VPAC2-R and PAC1-R receptors [35, 36] . VPAC2-R and PAC1-R knockout studies support an important role for both receptors in regulation of insulin release and insulin release in response to hypoglycemia [5 ,35,37-39] . Both VIP and PACAP stimulate insulin and glucagon secretion [35, 36] . Mice with either a VPAC2-R or PAC1-R deletion develop glucose intolerance [35, 38, 39] . VPAC2-R and PAC1-R knockout mice have impaired insulin secretion [35, 39] and PAC1-R knockout's also have both decreased glucagon secretion and PACAP was less effective potentiating glucose-induced insulin secretion which was reduced 50%, suggesting one-half of PACAP's effect is through PAC1-R [37, 38] . Animal studies demonstrate VPAC2-R activation by selective agonists significantly improves glucose-stimulated insulin secretion and improves glucose tolerance, leading to the proposal that selective activation of VPAC2-R receptors may be a new, novel therapeutic approach for the treatment of type II diabetes [35] . Both type I and II diabetes are characterized by a progressive beta-cell insufficiency with development of beta-cell apoptosis, although the pathogeneses of these processes differ for the two types of diabetes [36] . Both PAC1-R knockout studies as well as animal studies provide evidence that PACAP has trophic effects and can regulate both proliferation and cell viability of beta cells that therefore protect against diabetes [36] .
VPAC1-R knockout mice have growth retardation, an increased metabolic rate, increased insulin sensitivity and a reduced body fat mass with reduced serum leptin levels, suggesting VPAC1-R plays an important role in growth and basal energy expenditure [35, 39] . PAC1-R knockout mice display reduced food intake, hypoinsulinemia, lower body weight, and reduced white adipose tissue mass [40, 41] . These results are contradictory to experiments, which show that intracerebroventricular (ICV) injections of either PACAP or VIP inhibit food intake [42 ] . However, PAC1-R and VPAC1-R are expressed in the hypothalamus, but also widely in other CNS regions and therefore ICV injections could produce diverse effects [2 ,5 ,41] . In a recent study [42 ] , in the hypothalamic arcuate nucleus, a high proportion of proopiomelanocortin (POMC) neurons were found to express PAC1-R, PACAP activated neuropeptide Y (NPY) arcuate neurons, and arcuate PAC1-R activation mediated the ability of ICV PACAP to inhibit food intake [42 ,43] . These results suggest important roles for both PAC1-R and VPAC1-R in energy metabolism, lipid metabolism and regulation of body weight.
Knockout studies: gastrointestinal effects of VIP/PACAP Vasoactive intestinal peptide, PACAP and each of the three receptor subtypes are found widely in the gastrointestinal tract including in neural tissues [2 ,5 ,8 ]. In mice with a VIP knockout due to targeted mutation of the VIP gene [44] , the morphology of both the intestinal epithelium and smooth muscle are altered with a reduction in goblet cell mucous secretion and a marked increase in bowel muscle layers, which resulted in defective intestinal transit and a high risk of death due to gut stenosis. A wide variety of experimental studies support the conclusion that VIP acts as a neurotrasmitter/neuromodulator in both the brain and peripheral tissues [44] . It has been proposed that VIP is important in mediating gastrointestinal motility and is the primary regulator of descending relaxation of the peristaltic reflex [45] . The results of the VIP knockout study [44] are consistent with this proposal. A decrease in VIPergic innervation is reported in the human motility disorders, Hirschsprungs disease or children with constipation associated with symptoms of intestinal pseudo-obstruction; however, the role of VIP in their pathogenesis is unclear. It is proposed that the study of VIP knockout mice may be a good experimental model to explore VIP's role in these diseases because of the findings in the above study [44] .
Pituitary adenylate cyclase knockout studies also demonstrated that PACAP is an important neurotransmitter in mediating gastrointestinal motility [46] [47] [48] . Studying PACAP knockout mice, PACAP, as well as PHI, were found to function as inhibitory neurotransmitters in the circular muscle of the mouse antrum [46] [47] [48] . PHI and PACAP mediated sustained relaxation in the gastric antrum [46, 46] , and PACAP's action required the activation of a big conductance calcium-activated Kþ (BK) channel [48] .
Numerous pharmacological studies demonstrate that both PACAP and VIP can have growth-promoting effects on both normal tissues and neoplasms [2 ,34,49,50] . Factors contributing to the growth of gastric enterochromaffin-like cells (ECL cells) have received increased attention, because these cells proliferate in both hypergastrinemic states in humans and animals and the proliferation can result in the development of gastric carcinoid tumors, some of which are malignant [51, 52] . PAC1-Rs are found on ECL cells and their activation in rats stimulates both histamine release and gastric acid secretion, whereas in mice PACAP decreases acid secretion [53] . A recent study [54] using PAC1-R knockout mice further investigated PACAP's effect on gastric ECL cells, and found the PAC1-R knockout mice had a three-fold increase in basal acid output, increased gastric mucosal thickness, increases in parietal and total gastric cell counts, increased plasma gastrin levels and gastrin gene expression. This study demonstrates PAC1-R is important for maintaining the homeostasis of gastric acid secretion, is important in gastrin regulation and its dysregulation can result in gastric trophic effects [54] .
Knockout studies: cytoprotective, inflammatory and immunological effects of PACAP/VIP
Recent studies provide evidence that PACAP is not only a neuroprotective agent [55] (reviewed in latter section), but also has cytoprotective effects in other non-neural tissues [55] . PACAP has survival-promoting and cytoprotective affects in animal models of traumatic, ischemic conditions or inflammatory conditions [1, 55, 56] .
Studies in PAC1-R knockout mice demonstrate that endogenous PACAP and activation of PAC1-R protects against oxidative stress in the kidney [56] ; protects intestinal tissue from injury due to warm ischemia [57] ; provides colonic mucosal protection against experimentally induced colitis [58] ; has an anti-inflammatory role in preventing the development of septic shock [59, 60] ; and protects other tissues from various toxic injuries including cardiomyocytes, endothelial cells and lymphocytes [56] .
In both the experimental colitis study [58] and the study of lipopolysaccharide-induced septic shock [59] , PAC1-R knockout mice had higher levels of various proinflammatory cytokines (IL-6, etc.) leading the authors to propose this could contribute to their anti-inflammatory effects. Other studies have demonstrated both VIP and PACAP can decrease lipopolysaccharide-induced IL-6 production as well as neutrophils infiltration [60] , which have led to the suggestion that activation of PAC1-R might provide a novel approach for treatment of septic shock [60] . Similarly, using VIP knockout mice [61] , the presence of VIP is shown to protect animals from cyclophophamide-induced urinary bladder infections.
Both VIP and PACAP are present and released from immune cells, particularly Th2 cells and partially from the use of PAC or receptor knockout animals, both peptides have been shown to have profound effects on a number of immunological functions as well as having a general anti-inflammatory effect, inhibit cytokine and chemokine production, and stimulation of antigenspecific CD4 cells [12, 17] . This has led to the proposal that both VIP and PACAP are pleiotrophic immunomodulators, and that stable analogs of these two peptides could be useful for the treatment of a wide range of diseases including multiple sclerosis, rheumatoid arthritis, Parkinson's disease, Crohn's disease or autoimmune diabetes [12, 16, 62, 63] . The area has been the most expensively investigated using VIP/PACAP or their receptor knockout mice. It has been recently reviewed in a number of publications [2 ,5 ,50,64,65] and therefore only a few important recent results and areas of interest will be discussed below.
Studies of VIP knockout mice, VPAC2-R knockout mice, PAC1-R knockout mice and PAC knockout mice all demonstrate that VIP and PACAP as well as their receptors are important for normal circadian rhythm [5 ,66-70] .
Numerous studies provide evidence that PACAP has an important role in neural development and also has neuroprotective effect from various toxic injuries [1,5 ,50,55,71] . PACAP protected retinal neurons from UV-induced retinal injury [72] ; PAC knockout mice demonstrated impaired facial nerve regeneration after injury and enhanced neuro-inflammatory responses [73] and using PAC knockout mice, PACAP was shown to provide protection from experimental autoimmune encephalomyelitis [74] . PACAP protected mice against neurodegeneration, neurotoxicity and spinal cord injury [75] [76] [77] . In cells, PACAP protected against neurological insults from the excitatory amino acid, glutumate [78] , ceramide [79] , 6-hydroxydopamine [76] , ethanol [80] , betaamyloid(1-42) [81] and prions [82] . In PAC knockout mice after middle cerebral artery occlusion, the extent of damage to brain tissue is less than in normal animals and this effect may involve IL-6 [5 ,83,84] . In both these studies [83, 84] and a third study [85] in which the effect of PACAP administration after middle carotid artery occlusion in normal and PAC knockout animals was studied, it was concluded that endogenous PACAP afforded protection from ischemic injury [5 ] . Furthermore, the extent of cerebral edema is increased in PAC1-R knockout mice, suggesting that endogenous PACAP suppresses the formation of edema in ischemic brain tissue [86] .
It has been proposed that PACAP may play a role in mental diseases and that regulation of the PACAPergic signals could be a potential treatment for schizophrenia [87, 88 ] . Two PACAP-signaling cascades have been linked to schizophrenia [87, 88 ] . One pathway regulates the association between disrupted-in-schizophrenia 1(DISCI), which is associated with schizophrenia in family studies, and the DISCI-binding zinc-finger protein (DBZ) and the other inhibits stathmin1 expression [87, 88 ] . PACAP reduces the association of DISC1 and DBZ to induce neurite outgrowth and also effects the expression of stathmin1, which induces abnormal axonal arborization and is upregulated in PACAP knockout mice [87, 88 ]. In the brains of schizophrenia patients and PACAP knockout mice, stathmin1 is upregulated. Genetic variants of PACAP and PAC1-R are associated with schizophrenia in one study [89] , but not in another [90] . In the former study seven single-nucleotide polymorphisms (SNPs) of the PACAP [89] gene were examined in schizophrenia patients and controls and the major alleles of SNP3 and the minor of SNP5 were significantly overexpressed in addition to a significant association of a genetic variant of the PAC1 gene and schizophrenia [89] . In the brains of schizophrenic patients a reduced hippocampal volume was seen as well as poorer memory performance, a known hippocampal function [89] . PACAP knockout mice demonstrated depression-like behavior in a behavior test, suggesting that PACAP could be involved in this disorder [91] . The association of alterations of the PACAP gene and major depressive disorder (MDD) was studied by examining the frequencies of seven PACAP gene SNPs in 637 MDD patients and 967 healthy controls of Japanese descent [92 ] . The major allele, SNP3, of the PACAP gene was increased significantly in patients with MDD [87,88 ,92 ] . Also, SNP5, but not SNP1, SNP2, SNP4, SNP6 or SNP7 of the PACAP gene tended (P ¼ 0.058) to be associated with MDD [92 ] .
Conclusion
Vasoactive intestinal peptide and PACAP as well as the three classes of receptors mediating their actions (PAC1-R, PVAC1-R, VPAC2-R) are widely expressed in both the CNS and peripheral tissues. It has been difficult to establish which actions of these peptides are physiological or pharmacological or which are due to which receptor, in both normal processes and pathological processes. This has occurred because many tissues express both peptide as well as more than one class of their receptor; VIP and PACAP can interact with more than one class of these receptors with high affinity, and because of the lack of selective stable agonists or high affinity, potent antagonists for each receptor class. The recent use of receptor and peptide knockout animals has contributed important insights into their importance in a number of areas. These including their roles in metabolism, obesity, control of insulin release, various gastrointestinal disorders and in the CNS, particularly in regard to roles in regulation of circadian rhythm, neuroprotection and more recently, certain possible human disorders such as schizophrenia and depression. Each of these areas is briefly reviewed here concentrating on recent studies.
